Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome

Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease

(2012) Stephan von Haehling et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort

(2012) S Enhörning et al.   INTERNATIONAL JOURNAL OF OBESITY

Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction

(2011) Youlan L. Gu et al.   Clinical Research in Cardiology

Induction of Oxidative Stress and Human Leukocyte/Endothelial Cell Interactions in Polycystic Ovary Syndrome Patients with Insulin Resistance

(2011) Victor M. Victor et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Plasma Copeptin and the Risk of Diabetes Mellitus

(2010) Sofia Enhörning et al.   CIRCULATION

Cardiovascular risk in women with polycystic ovary syndrome

(2010) Francesco Giallauria et al.   Journal of Cardiovascular Medicine

Copeptin Improves Early Diagnosis of Acute Myocardial Infarction

(2010) Till Keller et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study

(2009) A. A. Voors et al.   EUROPEAN HEART JOURNAL

Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction

(2009) Tobias Reichlin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Copeptin: clinical use of a new biomarker

(2008) Nils G. Morgenthaler et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM